- Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
-
Sung HH, Lee SW
- KMID: 2315369
- Korean J Urol.
- 2012 Jun;53(6):377-385.
Oral phosphodiesterase type 5 (PDE5) inhibitors have provided non-invasive, effective, and well-tolerated treatments for patients with erectile dysfunction (ED). However, many patients with ED are unresponsive to 'on-demand' PDE5 inhibitors.... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment Strategy for Non-Responders to PDE5 Inhibitors
-
Park NC, Kim TN, Park HJ
- KMID: 2320852
- World J Mens Health.
- 2013 Apr;31(1):31-35.
Currently, phosphodiesterase type 5 (PDE5) inhibitors are the initial treatment option for erectile dysfunction. The reported efficacy of PDE5 inhibitors is about 70%, although it is significantly lower in difficult-to-treat... -
- CITED
-
- Close
- SHARE
-
- Close
- The risk factors, diagnosis and treatment guideline of erectile dysfunction
-
Moon DG
- KMID: 2195040
- J Korean Med Assoc.
- 2015 May;58(5):443-451.
- doi: 10.5124/jkma.2015.58.5.443
Erectile dysfunction (ED) can negatively impact the quality of life among men, and increasingly affects all age strata. This has led to an explosion of health information on ED both... -
- CITED
-
- Close
- SHARE
-
- Close
- Utilization, Safety, and Related Factors of Illegal Phosphodiesterase Type 5 Inhibitors in South Korean Men
-
Kim BG, Jung SY, Kwon KE, Park BJ
- KMID: 2226401
- Korean J Clin Pharm.
- 2015 Mar;25(1):50-55.
- doi: 10.0000/kjcp.2015.25.1.50
BACKGROUND: Phosphodiesterase Type 5 Inhibitors (PDE5Is), which are prescription drug in South Korea, have been concerned about misuse, overuse and illegal provision of the drugs. This study was performed to... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of the Efficacy, Safety and Patient Preference of the Phosphodiesterase Type 5 Inhibitors for the Patients with Erectile Dysfunction
-
Yoo C, Park J, Kim W, Hong B, Hong J, Ahn TY
- KMID: 2139764
- Korean J Urol.
- 2007 Feb;48(2):219-225.
- doi: 10.4111/kju.2007.48.2.219
PURPOSE: To compare the clinical efficacy and safety of three phosphodiesterase type 5 (PDE5) inhibitors in the treatment of mele erectile dysfunction according to patient preference. MATERIALS AND METHODS: Between... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacokinetics, Efficacy, and Safety of Selective Inhibitors of Phosphodiesterase Type 5 and Sublingual Apomorphine for the Treatment of Erectile Dysfunction
-
Kim SC
- KMID: 1894490
- Korean J Androl.
- 2002 Dec;20(3):113-125.
Oral pharmacotherapy has become the first-line therapy for the majority of patients with erectile dysfunction (ED) of broad-spectrum etiology since the introduction of oral sildenafil, a potent, selective inhibitor of phosphodiesterase type... -
- CITED
-
- Close
- SHARE
-
- Close
- Benign Prostatic Hyperplasia and Sexual Dysfunction
-
Cho IR
- KMID: 2298749
- Korean J Androl.
- 2010 Dec;28(3):145-153.
Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and declines in male sexual function are common manifestations of aging, and have been associated with each other in... -
- CITED
-
- Close
- SHARE
-
- Close
- The Influence of Treatment-emergent Adverse Reactions on Selecting Phosphodiesterase Type 5 Inhibitors
-
Yang CS, Kim SC
- KMID: 2294174
- Korean J Urol.
- 2006 Mar;47(3):272-278.
- doi: 10.4111/kju.2006.47.3.272
PURPOSE: This study was conducted to determine how treatment-emergent adverse reactions (ARs) of each of the phosphodiesterase type 5 inhibitors (PDE5Is) influenced the patient when selecting a drug. MATERIALS AND METHODS:... -
- CITED
-
- Close
- SHARE
-
- Close
- Obesity and Erectile Dysfunction: From Bench to Clinical Implication
-
Moon KH, Park SY, Kim YW
- KMID: 2443229
- World J Mens Health.
- 2019 May;37(2):138-147.
- doi: 10.5534/wjmh.180026
Obesity is a major public health issue worldwide and is frequently associated with erectile dysfunction (ED). Both conditions may share an internal pathologic environment, also known as common soil. Their... -
- CITED
-
- Close
- SHARE
-
- Close
- The Analysis of Clinical Efficacy of Phosphodiesterase 5 Inhibitors for Erectile Dysfunction using SS-Penogram
-
Choi KH, Soh BH, Oh CY, Kim JH, Choi HK
- KMID: 2298730
- Korean J Androl.
- 2009 Dec;27(3):194-200.
PURPOSE: As the first-line pharmacotherapy for erectile dysfunction (ED), phosphodiesterase type 5 (PDE5) inhibitors are widely used and their clinical efficacy is well established. But up to now, most of... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of phosphodiesterase type 5 inhibitors for the treatment of distal ureteral calculi: A systematic review and meta-analysis
-
Montes Cardona CE, GarcÃa-Perdomo HA
- KMID: 2368472
- Investig Clin Urol.
- 2017 Mar;58(2):82-89.
- doi: 10.4111/icu.2017.58.2.82
PURPOSE: To determine the efficacy of phosphodiesterase type 5 inhibitors (PDE5i) as medical expulsive therapy (MET) for the treatment of distal ureteral calculi. MATERIALS AND METHODS: A search strategy was conducted... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Sexual Enhancer Induced Fixed Drug Eruption
-
Lee SK, Kim DJ, Suh JH, Kim MS, Lee UH
- KMID: 2436688
- Korean J Dermatol.
- 2018 May;56(4):269-272.
Fixed drug eruption is a commonly reported mucocutaneous drug eruption. A 61-year-old male presented to our clinic with a complaint of an itchy round erythematous patch on the left hand... -
- CITED
-
- Close
- SHARE
-
- Close
- New PDEs Inhibitors for Erectile Dysfunction
-
Choi HK
- KMID: 2183138
- J Korean Med Assoc.
- 2003 Nov;46(11):1050-1056.
- doi: 10.5124/jkma.2003.46.11.1050
Phosphodiesterases (PDEs) are functionally diverse enzymes with wide organ and tissue distributions. Of these enzymes, PDE5 has received particular attention largely because of the introduction and widespread use of the... -
- CITED
-
- Close
- SHARE
-
- Close
- The Comparative Effects of PDE5 Inhibitors (Zaprinast, Sildenafil and Vardenafil) according to the Route of Administration in the Rabbit Model
-
Moon I, Choi S
- KMID: 2294035
- Korean J Urol.
- 2005 Aug;46(8):849-853.
Purpose: Intracavernosal (IC) PDE5 (phosphodiesterase type 5) inhibitors, at tissue levels approaching millimolar concentrations, have been reported to cause penile erection in the absence of sexual stimulation. The objectives of... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacological Management of Male Sexual Dysfunction
-
Chung WS
- KMID: 2185940
- J Korean Med Assoc.
- 2008 Aug;51(8):770-778.
- doi: 10.5124/jkma.2008.51.8.770
The erectile dysfunction (ED) and premature ejaculation (PE) are common medical conditions of male sexual dysfunction that affects the sexual lives of millions of men. While many drugs are now... -
- CITED
-
- Close
- SHARE
-
- Close
- The Analysis of Preference for Three PDE-5 Inhibitors
-
Yoon CJ, Lee SH, Moon KH, Yoo ES, Park JS, Lee KS, Shin HC, Lee YW
- KMID: 2226639
- Korean J Androl.
- 2005 Dec;23(3):116-121.
PURPOSE: To evaluate the preference factors for the treatment of erectile dysfunction (ED) with three different kinds of PDE-5 inhibitors. MATERIALS AND METHODS: This prospective, open-label study recruited 140 patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Usage and perceptions of phosphodiesterase type 5 inhibitors among the male partners of infertile couples
-
Song SH, Kim DS, Shim SH, Lim JJ, Yang SC
- KMID: 2161358
- Clin Exp Reprod Med.
- 2016 Mar;43(1):26-30.
- doi: 10.5653/cerm.2016.43.1.26
OBJECTIVE: We aimed to investigate the prevalence of erectile dysfunction (ED) and the usage of phosphodiesterase type 5 (PDE5) inhibitors for ED treatment in infertile couples. METHODS: A total of 260... -
- CITED
-
- Close
- SHARE
-
- Close
- A current perspective on post-micturition dribble in males
-
Yang DY, Lee WK
- KMID: 2444267
- Investig Clin Urol.
- 2019 May;60(3):142-147.
- doi: 10.4111/icu.2019.60.3.142
Post-micturition dribble (PMD) is the involuntary loss of urine immediately after urination. It is classified as a post-micturition symptom and is more common in males. Traditionally, PMD has been considered... -
- CITED
-
- Close
- SHARE
-
- Close
- Low-Intensity Shock Wave Therapy and Its Application to Erectile Dysfunction
-
Lei H, Liu J, Li H, Wang L, Xu Y, Tian W, Lin G, Xin Z
- KMID: 2320816
- World J Mens Health.
- 2013 Dec;31(3):208-214.
Although phosphodiesterase type 5 inhibitors (PDE5Is) are a revolution in the treatment of erectile dysfunction (ED) and have been marketed since 1998, they cannot restore pathological changes in the penis.... -
- CITED
-
- Close
- SHARE
-
- Close
- Penile Low-Intensity Shock Wave Therapy: A Promising Novel Modality for Erectile Dysfunction
-
Abu-Ghanem Y, Kitrey ND, Gruenwald , Appel B, Vardi Y
- KMID: 1988405
- Korean J Urol.
- 2014 May;55(5):295-299.
- doi: 10.4111/kju.2014.55.5.295
Penile extracorporeal low-intensity shock wave therapy (LIST) to the penis has recently emerged as a novel and promising modality in the treatment of erectile dysfunction (ED). LIST has angiogenic properties... -
- CITED
-
- Close
- SHARE
-
- Close
